Primary Pulmonary MALT Lymphoma about Four Cases and Literature Review

El Haouari A1, Tahiri L2, Moumna K2, Remmilink M1 and Salmon I1
1Department of Pathology, Hopital Erasme, Bruxelle, Belgium
2Department of Pathology, Hassan II Teaching Hospital, Fez, Morocco

Abstract

Bronchial-associated lymphoid tissue (BALT) lymphoma is a distinct subgroup of low-grade B-cell extranodal non-Hodgkin’s lymphoma, classified as marginal-zone lymphoma. This study was performed in order to assess the natural history of this rare entity. We evaluated retrospectively the clinical, radiological and histological features and to discuss the optimal management and prognostic factors through a literature review, of 4 patients with biopsy-proven BALT lymphoma collected at department of pathology of Erasme from 2010 to 2014. The group of four patients included three women and one man, with a median age of 69 years (Range: 45-84 years). One of 4 patients presented fever chest pain within bronchopneumonia, other patients were asymptomatic with an incidental finding after preoperative radiological assessment.

Computed tomography (CT), which is more sensitive than standard radiography, has demonstrated that the lesions are unilateral (n=3) and multiple (1 patient), without lymph node enlargement. All of our patients has a thoracoscopy diagnosis and therapeutic. Macroscopy: whitish lesions poorly defined. Microscopy: MALT lymphoma low grade (CD20+, bcl2+). All of our patients have just a local treatment without chemotherapy and three were alive after a follow extended.

Keywords: Lung; Extranal marginal zone/lowlgrade B-cell lymphoma of MALT type

Abbreviation: MALT: Mucosa-Associated Lymphoid Tissue; NSCLC: Non-Small-Cell Carcinoma; HP: Helicobacter pylori; NHL: Non-Hodgkin’s Lymphoma; BALT: Bronchus-Associated Lymphoid Tissue

Introduction

Mucosa-associated lymphoid tissue-derived (MALT) lymphoma is the most frequent subset of primary pulmonary lymphoma (PPL), and lung location represents 15% of cases [1-5]. Clinical presentation is not specific, and 36% of the patients are asymptomatic [5-12]. Diagnosis should be suspected in patients with chronic alveolar opacity, usually with an air bronchogram and no pleural effusion or mediastinal adenopathy [9,10,12,13].

Diagnosis requires biopsies such as bronchial, transbronchial, percutaneous or even invasive methods such as surgical open lung biopsies for histological analysis and immunohistologicalstaining. Histologically, primary pulmonary MALT-type lymphoma is characterized by a lymphoplasmacytic infiltrate with reactive germinal centers and the presence of lymphoepithelial lesions. There is no consensus on treatment. Current options are surgery, chemotherapy and radiotherapy.

Patients and Methods

We found four cases of PMALT (0.17%) from 2250 lung cancer collected at department of pathology of Erasme from 2010 to 2014.

Case 1

A 45 years-old woman, asymptomatic, who asked her doctor following the discovery of tuberculosis in a colleague of her husband, the realization of a chest X-ray showed right pulmonary condensation. Chest CT found a pulmonary mass in the right middle lobe hypermetabolic at PET scan (Figure 1). There was no lymph node or pleural abnormalities. No distant metastasis was evident. Transbronchial biopsy: large cell carcinoma (NSCLC). A sleeve right middle lobectomy and total dissection of the regional lymph nodes was performed through a right thoracotomy for cancer staging.

Pathological examination:

Macroscopy: Condensation poorly defined extent of 3 cm.

Microscopy: Low grade BALT (CD20+, bcl2+) invading the bronchial and vascular margins (Figure 2).

Later the patient was referred to the oncology service. There is no recurrence at 12 months.

Case 2

A 82 years-old woman with a history of rheumatoid arthritis, was admitted to our hospital for investigation of an abnormal chest shadow (a localized alveolar opacity with an air bronchogram) in preoperative chest radiography of a cure of tunnel carpien.

Chest CT shows a pulmonary mass in the upper right lobe, 6 cm long axis hypermetabolic at PET scan. There was no lymph node or pleural abnormalities. No distant metastasis was evident.

The decision of the meeting of the multidisciplinary discussion (RCP) is the realization of a right anterior segmentectomy and tumoraly analyze on intraoperative rapid frozen section examination. The pathological diagnosis was MALT lymphoma (CD79a+, CD20+, Ki67<2%, CK stain lymphoepithelial lesions). Vascular and bronchial...
decided, given the good evolution (3 years).

**Case 4**

A 68 years-old men, had no other medical history, admitted to our institution for the management of a left cerebral frontotemporal hemorrhage with mass effect and involvement in falcoriel, diagnosed in cerebral scanner performed in the context of loss of consciousness.

Chest CT showed pulmonary infiltrates in the right lower lobe and the left upper lobe with an air bronchogram clearly visible on chest radiography (Figures 3-9).

On the second day of admission, he developed sudden onset of dyspnea followed by cardiorespiratory arrest and succumbed despite resuscitative measures.

An autopsy was performed after obtaining written consent.

**Macroscopy**

- 2 large whitish lesion 4.5 cm and 2 cm longer axis located at the lower right lung lobe and whitish lesion 2.5 cm in the left upper lobe.
- Whitish liver lesion 2 cm in the Segment VI
- Diffuse whitish thickening of the gastric wall.
- Capsular thickening and whitish splenic lesion 3cm longer axis.

**Microscopy:** lung, gastric, splenic, hepatic and medullar localization of a MALT lymphoma.

**Discussion**

PPL is very rare. While extranodal forms represent 24-50% of cases of NHL [1-3], PPL represent only 3-4% of extranodal NHL, <1% of NHL, and only 0.5-1% of primary pulmonary malignancies [1,4,5]. Primary pulmonary NHL is most commonly represented by marginal zone B-cell lymphoma (MALT lymphoma) [1].

In our series, PMALT (4 cases) represents 0.7% of all lung cancers (2250 cases) diagnosed in our institution from 2010 to 2014.

MALT is a lymphoid tissue specializing in mucosal defense [1]. It was first described in the gastrointestinal tract of animal models, then in the human ileum.

The stomach is the most frequent site of MALT lymphoma and serves as a model for pulmonary MALT lymphoma. As in the stomach,
MALT is absent from the lung in physiological circumstances. During chronic antigenic stimulation (by *Helicobacter pylori*, for example), MALT can develop in the stomach and undergo secondary lymphomatous transformation arising from marginal zone B-cells.

No triggering antigens have so far been identified in the lung, but chronic antigenic stimulation in certain autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis, Hashimoto's thyroiditis and particularly Gougerot-Sjögren's syndrome) are considered to affect the onset of pulmonary MALT lymphoma [6].

In the present cases, one patient (case 2) had a history of a rheumatoid...
arthritides. Age of onset is ~50−60 yrs (12−79 yrs) and subjects <30 yrs are rarely affected [5,7−12]. The two sexes are equally affected [5,7−12]. In our series median age is 69 years (Range: 45−84 years) and the sex ratio was 3F/1H. Nearly half these patients are asymptomatic at diagnosis and are identified fortuitously on the basis of a radiological pulmonary anomaly [5,8−10,12]. When present, symptoms, such as cough, mild dyspnea, chest pain and occasionally haemoptysis, are non specific [5,7−12]. By definition, extra-pulmonary manifestations are restricted to general signs (fever and weight loss) and occur in less than one quarter of patients [5,8−10,12]. In our series, 3 patients were asymptomatic and one patient has fever chest pain within bronchopneumonia.

The usual radiological aspect (50−90% of cases) is a localized alveolar opacity, with a diameter of <5 cm and blurred or well-defined contours (according to the series); it is associated in nearly 50% of cases with an air bronchogram (Figure 3) [9,10,12].

In our series, all patients have an alveolar opacity in the chest radiography and 2 cases (50%) with an air bronchogram.

Computed tomography (CT) (Figure 1), which is more sensitive than standard radiography, has demonstrated that the lesions are usually bilateral (60−70%) and multiple (70−77%) [13]. Nearly all these lesions contain clear areas corresponding to an intact bronchial lumen (Figure 3). The presence of distended bronchi within the lesions is a good diagnostic sign, although the underlying mechanism is unexplained [13]. Less than 10% of patients have bilateral diffuse reticulo nodular opacities, atelectasia or pleural effusion [9,10,12]. CT scan reveal hilar and mediastinal adenopathy [7,12]. In our series, only one patient (case 4) had bilateral and multiple lesions in CT scan, no patient had a pleural effusion or mediastinal lymphadenopathy.

Bronchial endoscopy usually shows a normal macroscopic aspect [12], although abnormalities ranging from mucosal inflammation to bronchial stenosis can be observed [12]. The diagnostic yield of bronchial, and especially transbronchial, biopsy is higher when it targets visible endobronchial lesions or radiographic abnormalities [12]. However, the absence of specific signs in most of these samples necessitates further diagnostic investigations [5,7−12].

In our series, 2 patients underwent transbronchial biopsy could not conclude an accurate diagnosis. (case1: NSCIC; case 3: chronic inflammatory alteration, lympho-proliferative process to eliminate). Usually, the diagnosis of MALT-type NHL is based on histological examination of surgical samples or transthoracic biopsy material.

The macroscopic aspect is that of a whitish, soft and poorly-defined mass. Microscopically, MALT-type PPL is defined as a lesion [8,9,14−16] containing: 1) proliferation of small lymphoid cells analogous to the marginal zone cells of Peyer’s patches or spleen follicles, centrocyte-like cells and small lymphocytes, plasmocytes or monocytoid cells; 2) a lymphoepithelial lesion showing lymphoid cell migration from the marginal zone to the bronchiolar epithelium; 3) reactive follicular hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19]. Various hyperplasia; and 4) rare blastic cells. More unusual features include amyloid deposits (10,43) and granulomatous deposits [17−19].

In our series, one patient had simultaneous lung, gastric, splenic, hepatic and mediastinal localization of a MALT lymphoma.

The outcome of MALT-type PPL is generally favorable in most series, with a 5-yr survival rate of >80% and a median survival time of >10 yrs [5,7−9,14,12].

There is no consensus on treatment. The lack of an identified culprit antigen in the lung, contrary to the stomach (H. pylori), means that antibiotics effective on low-grade localized gastric lymphoma are inappropriate. Current treatment options are surgery, chemotherapy and radiotherapy [5,7,8,10]. The respective efficacy of these treatments cannot be assessed, however, owing to a lack of comparative series, and some authors even propose simple clinical monitoring [8]. Nevertheless, surgical resection is commonly preferred for localized tumors [5,7,8,10]. Exclusive chemotherapy is generally used for patients with bilateral or extrapulmonary involvement, relapse or progression.

In the present cases, 3 of our patients have localized tumors, were have just a local treatment and all were alive after a follow extended.

Conclusion

The MALT primary lung lymphoma must not be underestimated. Clinical manifestations and radiological characteristics are no specific. Usually, the diagnosis of MALT-type NHL is based on histological examination of surgical samples or transthoracic biopsy material.

There is no consensus on treatment. Nevertheless, surgical resection is commonly preferred for localized tumors. Although our series is small, the clinical and imaging features were consistent with those described in the literature, the prognosis was favorable even the follow-up is still short and the treatment was exclusively based on surgery.

References


OMICS International: Publication Benefits & Features

Unique features:
- Increased global visibility of articles through worldwide distribution and indexing
- Showcasing recent research output in a timely and updated manner
- Special issues on the current trends of scientific research

Special features:
- 700 Open Access Journals
- 30,000 editorial team
- Rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (portal), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles